NG004
Drugrepeated intrathecal injections of NG004
NCT Number: NCT06817577
This is the FIH, multicenter, open-label, sequential, multiple ascending dose trial of NG004 in patients with acute incomplete cervical SCI. The trial will evaluate the safety, tolerability, and PK of 4 dose regimens of NG004, and will evaluate the maximum tolerated dose of NG004.
Interested in participating?
Request Info18 year–70 year
All sexes
Interventional
Phase 1
Klinik für Querschnittgelähmte, Klinikum Bayreuth, Bayreuth, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
repeated intrathecal injections of NG004
Time frame: From treatment start up to 6 months
Time frame: After first and last intrathecal injection, measured at pre-dose and 1, 3, 6, 24, 48 hours post-dose.
Time frame: After last intrathecal injection up to 6 months
Time frame: Baseline up to 6 months
The ISNCSCI bilateral Upper Extremity Motor Score (UEMS) is determined by examining the muscle function within each of the 5 myotomes encompassing arm and hand function on each side of the body. A score ranging from 0 to 5 can be given to each myotome tested resulting in a maximum score of 50. Higher values indicate better recovery.
Time frame: Baseline to 6 months
The SCIM III questionnaire self-care score assesses activities of daily living including feeding, bathing, dressing, and grooming. The self-care score ranges 0-20. The higher scores correspond to better ability to carry out the self-care activities.
Contact information is provided by the study sponsor or research team.
NovaGo Therapeutics AG
Industry
A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients
Acronym: SPROUT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07090473
Acute Spinal Cord Injury (SCI), Acute Spinal Cord Injury of Traumatic Origin (tSCI)
San Francisco, California, United States
View Trial DetailsNCT06677229
Acute Spinal Cord Injury (SCI)
Córdoba, Spain
View Trial DetailsNCT07722962
Acute Spinal Cord Injury (SCI), Deafness, Autosomal Recessive 39
Iizuka, Fukuoka, Japan
View Trial DetailsNCT04460872
Androgen Deficiency, Bone Diseases
Gainesville, Florida, United States
View Trial Details